




Cascadian Therapeutics
Investor Relations Department
2601 4th Avenue, Suite 500
Seattle, WA 98121
United States

[Visit IR website](#) 
[Sign-up for email alerts](#) 

NASDAQ: CASC

Last Trade:	3.60
Trade Time:	4:00 PM ET Jun 27, 2017
Change:	-0.37  (-9.320%)
Day Range	3.56 - 4.02
52-Week Range	3.18 - 10.98
Volume	635,599

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

We are committed to serving the best interests of our shareholders. If you require assistance or have questions regarding the key shareholder information and financial reports available here please [contact](#) us.

... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- Jun 8, 2017*
[Cascadian Therapeutics' Lead Candidate, Tucatinib, Receives Orphan Drug Designation from FDA for Treatment of Breast Cancer Patients with Brain Metastases](#)
- May 31, 2017*
[Cascadian Therapeutics to Present at Jefferies 2017 Healthcare Conference](#)
- May 9, 2017*
[Cascadian Therapeutics Reports First Quarter 2017 Financial Results Conference Call Scheduled for Today at 8:30 a.m. ET](#)
- May 1, 2017*
[Cascadian Therapeutics to Report First Quarter 2017 Financial Results on May 9, 2017](#)
- Apr 5, 2017*
[Cascadian Therapeutics Highlights Preclinical Program Presentations at the American Association for Cancer Research Annual Meeting 2017](#)

Financials [\[View all \]](#)

- [First Quarter Financial Results](#)
- Mar 9, 2017*
[Annual Report \(10-K\)](#)
- Apr 26, 2017*
[Proxy Statement \(DEF 14A\)](#)
- May 9, 2017*
[Quarterly Report \(10-Q\)](#)
- Nov 7, 2016*
[Quarterly Report \(10-Q\)](#)
- Aug 8, 2016*
[Quarterly Report \(10-Q\)](#)